|
Jul 17
|
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
|
|
Jul 16
|
PureTech Announces Leadership Transition
|
|
Jun 26
|
Vor, with new CEO, changes course to target autoimmune disease
|
|
Jun 26
|
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
|
|
Apr 9
|
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
|
|
Apr 7
|
PureTech Health plc Statement Regarding Press Speculation
|
|
Feb 25
|
PureTech to Present at the Leerink Partners Global Healthcare Conference
|
|
Feb 12
|
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
|
|
Dec 11
|
PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024
|
|
Dec 9
|
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
|
|
Dec 5
|
FTSE 100 reshuffle sees Vistry kicked out and Games Workshop join the UK blue-chip index
|
|
Oct 9
|
Corrections & Amplifications
|
|
Oct 9
|
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
|
|
Oct 1
|
PureTech to Present at CHEST 2024 Annual Meeting
|
|
Sep 30
|
FDA approves PureTech’s KarXT to treat schizophrenia in adults
|
|
Sep 27
|
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
|
|
Sep 6
|
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
|
|
Jul 23
|
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
|
|
Jun 24
|
PureTech Health: Completion of Tender Offer & Total Voting Rights
|
|
Jun 24
|
PureTech Health: Results of the Tender Offer
|